Independent Research set a €80.00 ($95.24) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research report report published on Thursday morning. The firm currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on FRE. Goldman Sachs Group set a €78.00 ($92.86) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Wednesday, September 6th. Commerzbank set a €85.00 ($101.19) target price on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Monday, September 18th. UBS Group set a €74.00 ($88.10) price target on Fresenius SE & Co KGaA and gave the stock a neutral rating in a research note on Tuesday, September 19th. Berenberg Bank set a €90.00 ($107.14) price target on Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Wednesday, September 20th. Finally, Citigroup set a €83.00 ($98.81) price target on Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of €78.66 ($93.65).

Fresenius SE & Co KGaA (FRA FRE) opened at €67.06 ($79.83) on Thursday. Fresenius SE & Co KGaA has a fifty-two week low of €60.16 ($71.62) and a fifty-two week high of €80.00 ($95.24). The stock has a market cap of $37,040.00 and a P/E ratio of 21.36.

ILLEGAL ACTIVITY NOTICE: This story was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/fresenius-se-80-00-by-independent-research/1798208.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.